The Marque The Marque
The Marque
About Services Profiles Press Contact

Jim Mellon

Founder and Executive Chairman

Burnbrae Group

Douglas, IM

Burnbrae Group
Jim Mellon
Karen Mehiel
Kampack Inc
Michael Mendes
Just Desserts

Jim Mellon’s Biography

Jim Mellon is a British entrepreneur, investor and philanthropist with a broad range of interests. Through Burnbrae Group, his private investment company, Jim has considerable real estate holdings in the Isle of Man and Germany, as well as investments in public and private companies.

Jim’s core investment principles and beliefs are underpinned by meticulous analysis of new industries or major changes in markets. He has frequently predicted emerging market trends and identified global industry developments at an early stage. In his book ‘Wake Up!’ he famously foresaw the global financial crisis of 2008.

His 2017 book ‘Juvenescence' sparked a rush of capital into the expanding field of aging research, resulting in the formation of Juvenescence, a cutting-edge biopharmaceutical business focused on the commercialisation of therapies to delay, stop, and reverse aging.

Most recently, Jim wrote ‘Moo’s Law’, a book that focuses on investment opportunities in cellular agriculture and the new agrarian revolution. Jim co-founded Agronomics Ltd. in order to invest in companies leading the way in this sphere, and is its largest investor.

Jim is a member of the Board of Trustees of the American Federation for Aging Research (AFAR), the Buck Institute for Research on Aging and the Biogerontology Research Foundation. He is an Honorary Fellow of Oxford University's Oriel College, where he founded the Mellon Centre for Longevity. Jim also sits on the Advisory Board of the Center for the Future of Aging, part of the Milken Institute.

Jim Mellon’s Newsfeed

Why Billionaire Jim Mellon Is Predicting The End Of Meat, Dairy And Fish In 10 Years

According to Jim Mellon’s predictions, the food industry is set to see some big changes over the next decade.

The Telegraph
Mellon to list lithium miner on London’s junior market

Leading investor Jim Mellon is bringing his lithium venture to the stock exchange in London as the battery metal booms. Bradda Head, which wants to produce lithium in Arizona and Nevada, is set to join the junior AIM this month valued at around £16m.

View allHide

Jim Mellon’s Background

Burnbrae Group logo Burnbrae Group logo
Burnbrae Group
Founder and Executive Chairman
Jan 1990 - Present
Douglas, IM
The Burnbrae Group is a global investment company headquartered on the Isle of Man and focused on identifiable emerging trends. The company invests in the financial services, information technology, leisure, property, life sciences and mining sectors.
Co-founder and Chairman
Oct 2016 - Present
Juvenescence is a biotech company that has brought together a coalition of the best and most experienced scientists, drug developers, physicians, and investors to create cutting-edge therapies and products to improve the way we age. The company works closely with researchers worldwide and aims to empower people to plan their life journey and live longer.
View allHide

Jim Mellon’s Gallery

Board Positions

SalvaRx Group PLC
Board Member and Chairman
Jun 2015 - Present
SalvaRx Group is a pharmaceutical development company. Their focus is the development of effective pharmaceuticals for oncology patients. The company was previously known as 3legs Resources PLC.
Charlemagne Capital
Board member
Mar 2006 - Present
Charlemagne Capital was acquired by Fiera Capital in 2018. Jim also serves as Board member at Charlemagne Capital UK Ltd and Charlemagne Capital Iom Ltd.
View allHide

Advisory Roles

Milken Institute
Advisory Board: Centre for the Future of Aging
Santa Monica, CA, USA
The Milken Institute is a non-profit global organization that supports people to build meaningful and healthy lives, in which they can access effective education and gainful employment whilst developing and contributing to their broader communities.

Other Business Interests

AgeX Therapeutics
Alameda, CA, USA
AgeX Therapeutics is a biotechnology company focused on the development of innovative medicines and the commercialization of newly emerging therapeutics targeting human aging.

Current Board Positions

Agronomics Limited
Co-Founder & Non-Executive Director
Apr 2019 - Present
Douglas, IM
Agronomics Limited is investment vehicle taking stakes in companies pioneering alternatives to meat and fish. The idea is to grow meat cleanly from cells and to avoid all the environmental and animal welfare consequences of traditional meat production.
Webis Holdings PLC
Non-Executive Director
Jan 2012 - Present
Douglas, IM
Webis Holdings PLC is a holding company with subsidiaries functioning in the global gaming and technology sectors.
View allHide

Previous Board Positions

Portage Biotech
Non-Executive Director
Toronto, CA
Portage Biotech (NASDAQ: PRTG) is a clinical-stage immuno-oncology company dedicated to revolutionising research into cancer and the development of world-leading treatments that contribute significantly in helping cancer patients improve their quality of life.
FastForward Innovations Limited
Executive Co-Chairman
Saint Peter Port, GG
FastForward Innovations Limited's investment focus is on emerging, problem-solving, innovative technologies that will determine the future.
View allHide


The Plantbased Business Hour
Jun 2021
Jim joins Elysabeth Alfano on The Plantbased Business Hour to discuss his vision for the shifting global food supply chain.
The IEA: The New Agrarian Revolution with Jim Mellon
Video interview
Mar 2021
The Institute of Economic Affairs hosted a discussion with businessman Jim Mellon to discuss his latest book, Moo's Law: An Investor’s Guide to the New Agrarian Revolution. The IEA Director General, Mark Littlewood, chaired the discussion.
View allHide


Moo's Law
Dec 2020
Petersfield, UK
Jim has written Moo’s Law to help readers understand the landscape of investment in cultivated or plant-based proteins. He anticipates that global agriculture will be completely transformed by the growth of the cultivated meat technology industry over the next twenty years.
Juvenescence: Investing in the Age of Longevity
Sep 2017
Sudbury, UK
In this book, co-authors Jim Mellon and Al Chalabi present a roadmap to longevity, analysing the latest technologies available and describing how to benefit from them.
View allHide

Awards & Endorsements

American Federation for Aging Research
George E. and Marie J. Doty Award
New York, NY, USA
The American Federation for Aging Research has the provision of funding for biomedical research on aging at the heart of its mission. Jim was given the George E. and Marie J. Doty Award for his contribution to aging research.

Academic Appointments

Oriel College, University of Oxford
Honorary Fellow
Oxford, UK
Jim is an alumni of Oriel College, the fifth oldest of the University of Oxford’s colleges. Oriel was founded in 1326.

Speaking Engagements

Master Investor
Speaker, Master Investor Show 2019
Apr 2019
Jim presents on the main stage at the 2019 Master Investor Show. He offers the audience his perspective on market developments and thematic economic trends.

Charitable Interests

Lifeboat Foundation
Board member
Reno, NV, USA
The Lifeboat Foundation is a non-profit and non-governmental organization committed to promising scientific developments.

Jim Mellon’s Education

Oriel College, University of Oxford
Master's degree in Politics, Philosophy and Economics
1976 - 1979